Microvascular complications in diabetes: A growing concern for cardiologists

International Journal of Cardiology

Volumn 291, Issue , 2019, Pages 29-35

  Avogaro, Angelo ^a   Fadini, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Coronary heart disease; Diabetes mellitus; Heart failure; Microvascular complications

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; SAXAGLIPTIN; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

CARDIOLOGIST; CARDIOVASCULAR DISEASE; DIABETIC MACULAR EDEMA; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM; MICROVASCULATURE; PROSPECTIVE STUDY;

BLOOD GLUCOSE; CARDIOLOGISTS; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; MICROVESSELS; PROSPECTIVE STUDIES;

EID: 85062229837     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2019.02.030     Document Type: Review

References (81)

1. Solini, A., Penno, G., Bonora, E., Fondelli, C., Orsi, E., Arosio, M., Trevisan, R., Vedovato, M., Cignarelli, M., Andreozzi, F., Nicolucci, A., Pugliese, G., Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care 35 (2012), 143–149.
2. Voigt, M., Schmidt, S., Lehmann, T., Kohler, B., Kloos, C., Voigt, U.A., Meller, D., Wolf, G., Muller, U.A., Muller, N., Prevalence and progression rate of diabetic retinopathy in type 2 diabetes patients in correlation with the duration of diabetes. Exp. Clin. Endocrinol. Diabetes 126 (2018), 570–576.
3. Salvotelli, L., Stoico, V., Perrone, F., Cacciatori, V., Negri, C., Brangani, C., Pichiri, I., Targher, G., Bonora, E., Zoppini, G., Prevalence of neuropathy in type 2 diabetic patients and its association with other diabetes complications: the Verona Diabetic Foot Screening Program. J. Diabetes Complicat. 29 (2015), 1066–1070.
4. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H., Pedersen, O., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348 (2003), 383–393.
5. Marx, N., McGuire, D.K., Perkovic, V., Woerle, H.J., Broedl, U.C., von Eynatten, M., George, J.T., Rosenstock, J., Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point?. Diabetes Care 40 (2017), 1144–1151.
6. Lachin, J.M., Genuth, S., Cleary, P., Davis, M.D., Nathan, D.M., Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342 (2000), 381–389.
7. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359 (2008), 1577–1589.
8. Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62 (2013), 263–271.
9. Boright, A.P., Paterson, A.D., Mirea, L., Bull, S.B., Mowjoodi, A., Scherer, S.W., Zinman, B., Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54 (2005), 1238–1244.
10. Sandholm, N., Groop, P.H., Genetic basis of diabetic kidney disease and other diabetic complications. Curr. Opin. Genet. Dev. 50 (2018), 17–24.
11. Quinn, M., Angelico, M.C., Warram, J.H., Krolewski, A.S., Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39 (1996), 940–945.
12. Liu, E., Craig, J.E., Burdon, K., Diabetic macular oedema: clinical risk factors and emerging genetic influences. Clin Exp Optom 100 (2017), 569–576.
13. Ahlqvist, E., van Zuydam, N.R., Groop, L.C., McCarthy, M.I., The genetics of diabetic complications. Nat Rev Nephrol 11 (2015), 277–287.
14. Kristensen, S.L., Rorth, R., Jhund, P.S., Shen, L., Lee, M.M.Y., Petrie, M.C., Kober, L., McMurray, J.J.V., Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. Eur. J. Heart Fail. 20 (2018), 1549–1556.
15. Brownrigg, J.R., Hughes, C.O., Burleigh, D., Karthikesalingam, A., Patterson, B.O., Holt, P.J., Thompson, M.M., de Lusignan, S., Ray, K.K., Hinchliffe, R.J., Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 4 (2016), 588–597.
16. Shah, M.S., Brownlee, M., Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ. Res. 118 (2016), 1808–1829.
17. Hoseini, Z., Sepahvand, F., Rashidi, B., Sahebkar, A., Masoudifar, A., Mirzaei, H., NLRP3 inflammasome: its regulation and involvement in atherosclerosis. J. Cell. Physiol. 233 (2018), 2116–2132.
18. Prattichizzo, F., De Nigris, V., Spiga, R., Mancuso, E., La Sala, L., Antonicelli, R., Testa, R., Procopio, A.D., Olivieri, F., Ceriello, A., Inflammageing and metaflammation: the yin and yang of type 2 diabetes. Ageing Res. Rev. 41 (2018), 1–17.
19. Zhong, Q., Kowluru, R.A., Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. Invest. Ophthalmol. Vis. Sci. 54 (2013), 244–250.
20. Nelson, H., USA: objections to protective respirators. Lancet, 340, 1992, 1088.
21. Testa, R., Bonfigli, A.R., Prattichizzo, F., La Sala, L., De Nigris, V., Ceriello, A., The “metabolic memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients, 9, 2017.
22. Paneni, F., Costantino, S., Volpe, M., Luscher, T.F., Cosentino, F., Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. Atherosclerosis 230 (2013), 191–197.
23. Paneni, F., Mocharla, P., Akhmedov, A., Costantino, S., Osto, E., Volpe, M., Luscher, T.F., Cosentino, F., Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ. Res. 111 (2012), 278–289.
24. Zhong, Q., Kowluru, R.A., Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 62 (2013), 2559–2568.
25. Mishra, M., Zhong, Q., Kowluru, R.A., Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 55 (2014), 7256–7265.
26. Mishra, M., Kowluru, R.A., Epigenetic modification of mitochondrial DNA in the development of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 56 (2015), 5133–5142.
27. Duraisamy, A.J., Mishra, M., Kowluru, A., Kowluru, R.A., Epigenetics and regulation of oxidative stress in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 59 (2018), 4831–4840.
28. Ko, Y.A., Mohtat, D., Suzuki, M., Park, A.S., Izquierdo, M.C., Han, S.Y., Kang, H.M., Si, H., Hostetter, T., Pullman, J.M., Fazzari, M., Verma, A., Zheng, D., Greally, J.M., Susztak, K., Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol., 14, 2013, R108.
29. Bell, C.G., Teschendorff, A.E., Rakyan, V.K., Maxwell, A.P., Beck, S., Savage, D.A., Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med. Genet., 3, 2010, 33.
30. Al-Hasani, K., Mathiyalagan, P., El-Osta, A., Epigenetics, cardiovascular disease, and cellular reprogramming. J. Mol. Cell. Cardiol. 128 (2019), 129–133.
31. Lu, Z., Liu, N., Wang, F., Epigenetic regulations in diabetic nephropathy. J. Diabetes Res., 2017, 2017, 7805058.
32. Zhong, X., Chung, A.C., Chen, H.Y., Dong, Y., Meng, X.M., Li, R., Yang, W., Hou, F.F., Lan HY: miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56 (2013), 663–674.
33. Keating, S.T., van Diepen, J.A., Riksen, N.P., El-Osta, A., Epigenetics in diabetic nephropathy, immunity and metabolism. Diabetologia 61 (2018), 6–20.
34. Vejakama, P., Thakkinstian, A., Lertrattananon, D., Ingsathit, A., Ngarmukos, C., Attia, J., Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 55 (2012), 566–578.
35. Kiire, C.A., Porta, M., Chong, V., Medical management for the prevention and treatment of diabetic macular edema. Surv. Ophthalmol. 58 (2013), 459–465.
36. Galan, M., Kassan, M., Choi, S.K., Partyka, M., Trebak, M., Henrion, D., Matrougui, K., A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 60 (2012), 71–80.
37. Fadini, G.P., Losordo, D., Dimmeler, S., Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ. Res. 110 (2012), 624–637.
38. Rigato, M., Bittante, C., Albiero, M., Avogaro, A., Fadini, G.P., Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 100 (2015), 2666–2672.
39. Busik, J.V., Tikhonenko, M., Bhatwadekar, A., Opreanu, M., Yakubova, N., Caballero, S., Player, D., Nakagawa, T., Afzal, A., Kielczewski, J., Sochacki, A., Hasty, S., Li Calzi, S., Kim, S., Duclas, S.K., Segal, M.S., Guberski, D.L., Esselman, W.J., Boulton, M.E., Grant, M.B., Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J. Exp. Med. 206 (2009), 2897–2906.
40. Albiero, M., Poncina, N., Ciciliot, S., Cappellari, R., Menegazzo, L., Ferraro, F., Bolego, C., Cignarella, A., Avogaro, A., Fadini, G.P., Bone marrow macrophages contribute to diabetic stem cell mobilopathy by producing oncostatin M. Diabetes 64 (2015), 2957–2968.
41. Oikawa, A., Siragusa, M., Quaini, F., Mangialardi, G., Katare, R.G., Caporali, A., van Buul, J.D., van Alphen, F.P., Graiani, G., Spinetti, G., Kraenkel, N., Prezioso, L., Emanueli, C., Madeddu, P., Diabetes mellitus induces bone marrow microangiopathy. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 498–508.
42. Fadini, G.P., Ferraro, F., Quaini, F., Asahara, T., Madeddu, P., Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl. Med. 3 (2014), 949–957.
43. Wong, T.Y., Cheung, C.M., Larsen, M., Sharma, S., Simo, R., Diabetic retinopathy. Nat Rev Dis Primers, 2, 2016, 16012.
44. Simo, R., Stitt, A.W., Gardner, T.W., Neurodegeneration in diabetic retinopathy: does it really matter?. Diabetologia 61 (2018), 1902–1912.
45. Bandello, F., Battaglia Parodi, M., Lanzetta, P., Loewenstein, A., Massin, P., Menchini, F., Veritti, D., Diabetic Macular Edema. Dev. Ophthalmol. 58 (2017), 102–138.
46. Klein, R., Knudtson, M.D., Lee, K.E., Gangnon, R., Klein, B.E., The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 116 (2009), 497–503.
47. Complications, Microvascular, Care, Foot, Standards of medical care in diabetes-2019. Diabetes Care 42 (2019), S124–S138.
48. Duh, E., Aiello, L.P., Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48 (1999), 1899–1906.
49. Orasanu, G., Plutzky, J., The pathologic continuum of diabetic vascular disease. J. Am. Coll. Cardiol. 53 (2009), S35–S42.
50. Kampschulte, M., Brinkmann, A., Stieger, P., Sedding, D.G., Dierkes, C., Bohle, R.M., Krombach, G., Ritman, E.L., Langheinrich, A.C., Quantitative CT imaging of the spatio-temporal distribution patterns of vasa vasorum in aortas of apoE−/−/LDL−/− double knockout mice. Atherosclerosis 212 (2010), 444–450.
51. Kockx, M.M., Cromheeke, K.M., Knaapen, M.W., Bosmans, J.M., De Meyer, G.R., Herman, A.G., Bult, H., Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 440–446.
52. Taqueti, V.R., Di Carli, M.F., Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J. Am. Coll. Cardiol. 72 (2018), 2625–2641.
53. Sluimer, J.C., Kolodgie, F.D., Bijnens, A.P., Maxfield, K., Pacheco, E., Kutys, B., Duimel, H., Frederik, P.M., van Hinsbergh, V.W., Virmani, R., Daemen, M.J., Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J. Am. Coll. Cardiol. 53 (2009), 1517–1527.
54. Tesfaye, S., Vileikyte, L., Rayman, G., Sindrup, S.H., Perkins, B.A., Baconja, M., Vinik, A.I., Boulton, A.J., Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab. Res. Rev. 27 (2011), 629–638.
55. Chammas, N.K., Hill, R.L., Edmonds, M.E., Increased mortality in diabetic foot ulcer patients: the significance of ulcer type. J. Diabetes Res., 2016, 2016, 2879809.
56. Zaccardi, F., Khan, H., Laukkanen, J.A., Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis. Int. J. Cardiol. 177 (2014), 535–537.
57. Scognamiglio, R., Avogaro, A., Casara, D., Crepaldi, C., Marin, M., Palisi, M., Mingardi, R., Erle, G., Fasoli, G., Dalla Volta, S., Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 31 (1998), 404–412.
58. Kim, S.J., Lee, J.D., Ryu, Y.H., Jeon, P., Shim, Y.W., Yoo, H.S., Park, C.Y., Lim, S.G., Evaluation of cardiac sympathetic neuronal integrity in diabetic patients using iodine-123 metaiodobenzylguanidine. Eur. J. Nucl. Med. 23 (1996), 401–406.
59. Paolillo, S., Rengo, G., Pagano, G., Pellegrino, T., Savarese, G., Femminella, G.D., Tuccillo, M., Boemio, A., Attena, E., Formisano, R., Petraglia, L., Scopacasa, F., Galasso, G., Leosco, D., Trimarco, B., Cuocolo, A., Perrone-Filardi, P., Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care 36 (2013), 2395–2401.
60. Thaung, H.P., Baldi, J.C., Wang, H.Y., Hughes, G., Cook, R.F., Bussey, C.T., Sheard, P.W., Bahn, A., Jones, P.P., Schwenke, D.O., Lamberts, R.R., Increased efferent cardiac sympathetic nerve activity and defective intrinsic heart rate regulation in type 2 diabetes. Diabetes 64 (2015), 2944–2956.
61. Reno, C.M., Skinner, A., Bayles, J., Chen, Y.S., Daphna-Iken, D., Fisher, S.J., Severe hypoglycemia-induced sudden death is mediated by both cardiac arrhythmias and seizures. Am. J. Physiol. Endocrinol. Metab. 315 (2018), E240–E249.
62. He, F., Xia, X., Wu, X.F., Yu, X.Q., Huang, F.X., Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis. Diabetologia 56 (2013), 457–466.
63. KDOQI Clinical Practice Guideline for Diabetes and CKD, 2012 update. Am. J. Kidney Dis. 60 (2012), 850–886.
64. Jeansson, M., Gawlik, A., Anderson, G., Li, C., Kerjaschki, D., Henkelman, M., Quaggin, S.E., Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J. Clin. Invest. 121 (2011), 2278–2289.
65. Wharram, B.L., Goyal, M., Wiggins, J.E., Sanden, S.K., Hussain, S., Filipiak, W.E., Saunders, T.L., Dysko, R.C., Kohno, K., Holzman, L.B., Wiggins, R.C., Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J. Am. Soc. Nephrol. 16 (2005), 2941–2952.
66. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, Levey AS, de Jong PE, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011;79:1341–1352.
67. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J, de Jong PE, El-Nahas M, Eckardt KU, Kasiske BL, Wright J, Appel L, Greene T, Levin A, Djurdjev O, Wheeler DC, Landray MJ, Townend JN, Emberson J, Clark LE, Macleod A, Marks A, Ali T, Fluck N, Prescott G, Smith DH, Weinstein JR, Johnson ES, Thorp ML, Wetzels JF, Blankestijn PJ, van Zuilen AD, Menon V, Sarnak M, Beck G, Kronenberg F, Kollerits B, Froissart M, Stengel B, Metzger M, Remuzzi G, Ruggenenti P, Perna A, Heerspink HJ, Brenner B, de Zeeuw D, Rossing P, Parving HH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T: Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011;79:1331–1340.
68. Edwards, N.C., Moody, W.E., Chue, C.D., Ferro, C.J., Townend, J.N., Steeds, R.P., Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc. Imaging 7 (2014), 703–714.
69. Di Lullo, L., House A, Gorini, A., Santoboni, A., Russo, D., Ronco, C., Chronic kidney disease and cardiovascular complications. Heart Fail. Rev. 20 (2015), 259–272.
70. Stehouwer, C.D., Smulders, Y.M., Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J. Am. Soc. Nephrol. 17 (2006), 2106–2111.
71. Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T: Microalbuminuria. Implications for micro- and macrovascular disease. Diabetes Care 1992;15:1181–1191.
72. Jager, A., van Hinsbergh, V.W., Kostense, P.J., Emeis, J.J., Nijpels, G., Dekker, J.M., Heine, R.J., Bouter, L.M., Stehouwer, C.D., C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 22 (2002), 593–598.
73. Jackson, C.E., Solomon, S.D., Gerstein, H.C., Zetterstrand, S., Olofsson, B., Michelson, E.L., Granger, C.B., Swedberg, K., Pfeffer, M.A., Yusuf, S., McMurray, J.J., Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374 (2009), 543–550.
74. Arnlov, J., Evans, J.C., Meigs, J.B., Wang, T.J., Fox, C.S., Levy, D., Benjamin, E.J., D'Agostino, R.B., Vasan, R.S., Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112 (2005), 969–975.
75. Davies, M.J., D'Alessio, D.A., Fradkin, J., Kernan, W.N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D.J., Buse, J.B., Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 (2018), 2669–2701.
76. Muskiet, M.H.A., Wheeler, D.C., Heerspink, H.J.L., New pharmacological strategies for protecting kidney function in type 2 diabetes. Lancet Diabetes Endocrinol. 7:5 (2018), 397–412.
77. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M.L., Woo, V., Hansen, O., Holst, A.G., Pettersson, J., Vilsboll, T., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375 (2016), 1834–1844.
78. Douros, A., Filion, K.B., Yin, H., Yu, O.H., Etminan, M., Udell, J.A., Azoulay, L., Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care 41 (2018), 2330–2338.
79. Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., Udell, J.A., Mosenzon, O., Im, K., Umez-Eronini, A.A., Pollack, P.S., Hirshberg, B., Frederich, R., Lewis, B.S., McGuire, D.K., Davidson, J., Steg, P.G., Bhatt, D.L., Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 132, 2015, e198.
80. Margulies, K.B., Hernandez, A.F., Redfield, M.M., Givertz, M.M., Oliveira, G.H., Cole, R., Mann, D.L., Whellan, D.J., Kiernan, M.S., Felker, G.M., McNulty, S.E., Anstrom, K.J., Shah, M.R., Braunwald, E., Cappola, T.P., Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
81. Fadini, G.P., Sarangdhar, M., Avogaro, A., Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Res. Care, 6, 2018, e000475.